Rakhshandra Talpur1, Dawen Sui2, Pamela Gangar3, Bouthaina S Dabaja4, Madeleine Duvic3. 1. Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: rtalpur@mdanderson.org. 2. Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX. 3. Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX. 4. Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX.
Abstract
INTRODUCTION: Large cell transformation (LCT) of mycosis fungoides (MF) is associated with an aggressive clinical course, poor overall survival (OS), and variable CD30 expression. PATIENTS AND METHODS: We retrospectively analyzed 1900 MF/Sézary syndrome patients' clinical, histologic and immunophenotype and identified 187 patients seen between 1982 and 2012. RESULTS: Most advanced stage patients with LCT were male 86 of 155 (55.4%) and 69 were female (44.5%). Incidence of LCT (n = 187) was 9.8% (187/1900) in skin and/or nodes of the entire MF/SS database population (n = 1900). Advanced stage patients represented 83% of patients whose median OS was 4.1 years (95% confidence interval [CI], 3.5-5.4). Early stage patients represented 17% with OS of 8.0 years. Among 187 LCT patients, 136 patients (73%) were diagnosed with LCT at the time of initial diagnosis of MF. Their median OS was 3.6 years (95% CI, 3.3-5.3). Of the 51 patients who had LCT diagnosed after their initial diagnosis of MF, their median OS was 8.8 years (P = .0001; 95% CI, 1.6-4.1). The OS for all LCT patients was 4.8 years, for patients older than 60 years of age OS was 3.7 years (95% CI, 2.7-5.4) and was 6.2 years (95% CI, 4.5-9.8) for patients younger than 60 years of age (P = .0001). An increased lactate dehydrogenase level was associated with a decreased OS (P = .03; hazard ratio, 1.5; 95% CI, 1.0-2.2). Patients with CD30 expression in ≥ 10% of the lymphocytes in skin biopsies were 40% more likely to survive than patients with low expression. CONCLUSION: In summary, risk factors associated with disease progression were advanced age, LCT at the time of initial diagnosis of MF, high levels of lactate dehydrogenase, and CD30 expression < 10%.
INTRODUCTION: Large cell transformation (LCT) of mycosis fungoides (MF) is associated with an aggressive clinical course, poor overall survival (OS), and variable CD30 expression. PATIENTS AND METHODS: We retrospectively analyzed 1900 MF/Sézary syndrome patients' clinical, histologic and immunophenotype and identified 187 patients seen between 1982 and 2012. RESULTS: Most advanced stage patients with LCT were male 86 of 155 (55.4%) and 69 were female (44.5%). Incidence of LCT (n = 187) was 9.8% (187/1900) in skin and/or nodes of the entire MF/SS database population (n = 1900). Advanced stage patients represented 83% of patients whose median OS was 4.1 years (95% confidence interval [CI], 3.5-5.4). Early stage patients represented 17% with OS of 8.0 years. Among 187 LCT patients, 136 patients (73%) were diagnosed with LCT at the time of initial diagnosis of MF. Their median OS was 3.6 years (95% CI, 3.3-5.3). Of the 51 patients who had LCT diagnosed after their initial diagnosis of MF, their median OS was 8.8 years (P = .0001; 95% CI, 1.6-4.1). The OS for all LCT patients was 4.8 years, for patients older than 60 years of age OS was 3.7 years (95% CI, 2.7-5.4) and was 6.2 years (95% CI, 4.5-9.8) for patients younger than 60 years of age (P = .0001). An increased lactate dehydrogenase level was associated with a decreased OS (P = .03; hazard ratio, 1.5; 95% CI, 1.0-2.2). Patients with CD30 expression in ≥ 10% of the lymphocytes in skin biopsies were 40% more likely to survive than patients with low expression. CONCLUSION: In summary, risk factors associated with disease progression were advanced age, LCT at the time of initial diagnosis of MF, high levels of lactate dehydrogenase, and CD30 expression < 10%.
Authors: Ivan V Litvinov; Michael T Tetzlaff; Philippe Thibault; Pamela Gangar; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Kevin Pehr; Victor G Prieto; Elham Rahme; Nathalie Provost; Martin Gilbert; Denis Sasseville; Madeleine Duvic Journal: Oncoimmunology Date: 2017-03-17 Impact factor: 8.110
Authors: Shiun Chang; Lucia Seminario-Vidal; Kenneth Y Tsai; Pei-Ling Chen; Xiaofei Song; Alvaro de Mingo Pulido; Leticia Tordesillas; Xingzhi Song; Rhianna A Reed; Andrea Harkins; Shannen Whiddon; Jonathan V Nguyen; Carlos Moran Segura; Chaomei Zhang; Sean Yoder; Zena Sayegh; Yun Zhao; Jane L Messina; Carly M Harro; Xiaohui Zhang; José R Conejo-Garcia; Anders Berglund; Lubomir Sokol; Jianhua Zhang; Paulo C Rodriguez; James J Mulé; Andrew P Futreal Journal: Cancer Discov Date: 2022-05-02 Impact factor: 38.272
Authors: Philippe Lefrançois; Pingxing Xie; Linghua Wang; Michael T Tetzlaff; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Nathalie Provost; Martin Gilbert; Xiao Ni; Denis Sasseville; David A Wheeler; Madeleine Duvic; Ivan V Litvinov Journal: Oncoimmunology Date: 2018-05-31 Impact factor: 8.110
Authors: Frederick Lansigan; Steven M Horwitz; Lauren C Pinter-Brown; Kenneth R Carson; Andrei R Shustov; Steven T Rosen; Barbara Pro; Eric D Hsi; Massimo Federico; Christian Gisselbrecht; Marc Schwartz; Lisa A Bellm; Mark Acosta; Francine M Foss Journal: Clin Lymphoma Myeloma Leuk Date: 2020-05-11